<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168201">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950299</url>
  </required_header>
  <id_info>
    <org_study_id>VCU HM20000024</org_study_id>
    <nct_id>NCT01950299</nct_id>
  </id_info>
  <brief_title>IL-1 Blockade in Acute Myocardial Infarction (VCU-ART3)</brief_title>
  <acronym>VCU-ART3</acronym>
  <official_title>Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: VCU-ART3 Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra
      standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)
      measuring the effects on the acute rise and fall of the plasma C reactive protein levels
      during the first 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute phase response (CRP levels)</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo corrected difference in the area-under-the-curve for CRP up to day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic volume indices change</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo corrected interval change in left ventricular end-systolic volume indices over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo-corrected interval changes in left ventricular ejection fraction over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>New onset of heart failure symptoms (NYHA II-IV)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg</intervention_name>
    <description>Anakinra 100 mg starting immediately and then every 24 hours</description>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg</intervention_name>
    <description>Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)</description>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo injections twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria
        and NONE of the Exclusion criteria.

          1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and
             ECG evidence of ST segment elevation (&gt;1 mm) in 2 or more anatomically contiguous
             leads that is new or presumably new

          2. Planned or completed coronary angiogram for potential intervention

          3. Age&gt;21

        EXCLUSION CRITERIA:

          -  Inability to give informed consent

          -  Pregnancy

          -  Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association
             III-IV)

          -  Preexisting severe left ventricular dysfunction (EF&lt;20%)

          -  Preexisting severe valvular heart disease

          -  Active infections (acute or chronic)

          -  Recent (&lt;14 days) or active use of anti-inflammatory drugs (not including NSAIDs or
             corticosteroids used for IV dye allergy only)

          -  Chronic inflammatory disease (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus)

          -  Known active malignancy of any type, or prior diagnosis in the past 10 years

          -  Anticipated need for cardiac surgery

          -  Active cancer (or prior diagnosis of cancer within the past 10 years)

          -  Neutropenia (absolute neutrophil count&lt;1,800/mm3)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <phone>804-828-0513</phone>
    <email>aabbate@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <phone>804-828-4583</phone>
    <email>bvantassell@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <phone>804-828-0513</phone>
      <email>aabbate@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Van Tassell, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
